Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer A systematic literature review

British Journal of Cancer

Volumn 107, Issue 7, 2012, Pages 1069-1074

  Borley, J ^a   Wilhelm Benartzi, C ^a   Brown, R ^a,b   Ghaem Maghami, S ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

debulking surgery; molecular biomarkers; ovarian cancer

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CANCER SURGERY; CANCER THERAPY; CYTOREDUCTIVE SURGERY; DNA METHYLATION; GENE; GENE EXPRESSION; HUMAN; MTDH GENE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOMATOMEDIN C RECEPTOR GENE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84866952001     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.376     Document Type: Article

References (59)

1. An Y, Cai L, Wang Y, Zhu D, Guan Y, Zheng J (2009) Local expression of insulin-like growth factor-I, insulin-like growth factor-I receptor, and estrogen receptor alpha in ovarian cancer. Onkologie 32(11): 638-644
2. Bar JK, Har"ozińska A, Popiela A, Noga L (2001) Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy. Tumour Biol 22(2): 83-91
3. Barnett JC, Bean SM, Whitaker RS, Kondoh E, Baba T, Fujii S, Marks JR, Dressman HK, Murphy SK, Berchuck A (2010) Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. Gynecol Oncol 116(3): 556-562
4. Berchuck A, Iversen ES, Lancaster JM, Dressman HK, West M, Nevins JR, Marks JR (2004) Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 190(4): 910-925
5. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett JC, Boyd J, Birrer MJ (2008) A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68(13): 5478-5486
6. Bowtell DD (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10(11): 803-808
7. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5): 1248-1259
8. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353): 609-615
9. Cancer Research UK (2011) CancerStats report-Ovarian Cancer UK, Cancer Research UK
10. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR (2009) Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114(1): 26-31
11. Chi DS, Schwartz PE (2008) Cytoreduction vs neoadjuvant chemotherapy for ovarian cancer. Gynecol Oncol 111(3): 391-399
12. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA, Group IMW (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377(9760): 127-138
13. Colombo PE, Mourregot A, Fabbro M, Gutowski M, Saint-Aubert B, Quenet F, Gourgou S, Rouanet P (2009) Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol 35(2): 135-143
14. Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB (2005) Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol 23(34): 8802-8811
15. Dai W, Teodoridis J, Zeller C, Graham JS, Hersey JM, Flanagan JM, Stronach EA, Millan DW, Siddiqui N, Paul J, Brown R (2011) Systematic CpG Islands methylation profiling of genes in the Wnt pathway in epithelial Ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res 17(12): 4052-4062
16. De Graeff P, Crijns AP, de Jong S, Boezen M, Post WJ, de Vries EG, van der Zee AG, de Bock GH (2009) Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer 101(1): 149-159
17. Demidenko E (2007) Sample size determination for logistic regression revisited. Stat Med 26: 3385-3397
18. Dogan E, Saygili U, Tuna B, Gol M, Gürel D, Acar B, Koyuncuoglu M (2005) p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis. Gynecol Oncol 97(1): 46-52
19. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS (2008) The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 108(2): 276-281
20. Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S (2003) Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90(2): 390-396
21. Emdad L, Lee SG, Su ZZ, Jeon HY, Boukerche H, Sarkar D, Fisher PB (2009) Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis. Proc Natl Acad Sci USA 106(50): 21300-21305
22. Emdad L, Sarkar D, Su ZZ, Lee SG, Kang DC, Bruce JN, Volsky DJ, Fisher PB (2007) Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. Pharmacol Ther 114(2): 155-170
23. Ferrandina G, Fagotti A, Salerno MG, Natali PG, Mottolese M, Maneschi F, De Pasqua A, Benedetti-Panici P, Mancuso S, Scambia G (1999) p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer 81(4): 733-740
24. Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, Jacobs I, Widschwendter M (2008) HOXA11 DNA methylation-a novel prognostic biomarker in ovarian cancer. Int J Cancer 123(3): 725-729
25. FIGO (1987) Changes in definitions of clinical staging for carcinoma of the cervix and ovary: International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 156(1): 263-264
26. Fotopoulou C, Richter R, Braicu EI, Schmidt SC, Lichtenegger W, Sehouli J (2010) Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients. Eur J Surg Oncol 36(12): 1202-1210
27. Geisler JP, Geisler HE, Wiemann MC, Givens SS, Zhou Z, Miller GA (1997) Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol 66(3): 435-438
28. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS (1994) The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170(4): 974-979; discussion 979-980
29. Hosono S, Kajiyama H, Terauchi M, Shibata K, Ino K, Nawa A, Kikkawa F (2007) Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. Br J Cancer 96(2): 314-320
30. Ibeanu OA, Bristow RE (2010) Predicting the outcome of cytoreductive surgery for advanced ovarian cancer: a review. Int J Gynecol Cancer 21(S1): S1-S11
31. Jewell EL, Darcy KM, Hutson A, Lee PS, Havrilesky LJ, Grace LA, Berchuck A, Secord AA (2009) Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 115(3): 424-429
32. Komiyama S, Kurahashi T, Ishikawa M, Tanaka K, Komiyama M, Mikami M, Udagawa Y (2011) Expression of TGFb1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin. Oncol Rep 25(4): 1131-1138
33. Leoutsakou T, Talieri M, Scorilas A (2006) Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer. Biochem Biophys Res Commun 344(2): 667-674
34. Levine DA, Bonome T, Olshen AB, Bogomolniy F, Brady J, Pise-Masison C, Radonovich M, Chi DS, Birrer MJ, Boyd J (2004) Gene expression profiling of advanced ovarian cancers to predict the outcome of primary surgical cytoreduction. J Clin Oncol 22: 14S
35. Li C, Liu J, Lu R, Yu G, Wang X, Zhao Y, Song H, Lin P, Sun X, Yu X, Zhang Y, Ning X, Geng J (2011) AEG-1 overexpression: a novel indicator for peritoneal dissemination and lymph node metastasis in epithelial ovarian cancers. Int J Gynecol Cancer 21(4): 602-608
36. Lin F, Lin K, Xie X, Zhou C (2010) Increased ERCC1 protein expression is associated with suboptimal debulking in advanced epithelial ovarian cancer. Anticancer Res 30(6): 2447-2452
37. Liu L, Wu J, Ying Z, Chen B, Han A, Liang Y, Song L, Yuan J, Li J, Li M (2010) Astrocyte elevated gene-1 upregulates matrix metalloproteinase-9 and induces human glioma invasion. Cancer Res 70(9): 3750-3759
38. Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Puopolo M, Schwartz P, Yu H (2006) Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. Gynecol Oncol 103(3): 990-995
39. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Diagnostics SSotN-EWGoC (2005) Reporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2(8): 416-422
40. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK (2008) Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359(25): 2641-2650
41. Nguyen HN, Averette HE, Hoskins W, Penalver M, Sevin BU, Steren A (1993) National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival. Cancer 7212: 3663-3670
42. Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein G, Sood AK (2011) Silencing of p130Cas in Ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst 103(21): 1596-1612
43. Pomel C, Barton DP, McNeish I, Shepherd J (2008) A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOG 115(7): 808-810
44. Préfontaine M, Gelfand AT, Donovan JT, Powell JL (1994) Reproducibility of tumor measurements in ovarian cancer: a study of interobserver variability. Gynecol Oncol 55(1): 87-90
45. Reimer D, Steppan I, Wiedemair A, Concin N, Hofstetter G, Marth C, Müller-Holzner E, Zeimet AG (2007) Soluble isoforms but not the transmembrane form of coxsackie-adenovirus receptor are of clinical relevance in epithelial ovarian cancer. Int J Cancer 120(12): 2568-2575
46. Rosen DG, Yang G, Deavers MT, Malpica A, Kavanagh JJ, Mills GB, Liu J (2006) Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 106(9): 1925-1932
47. Seo SS, Song YS, Kang DH, Park IA, Bang YJ, Kang SB, Lee HP (2004) Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol Oncol 92(3): 927-935
48. Shih KK, Chi DS (2010) Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol 21(2): 75-80
49. Simpson BJ, Phillips HA, Lessells AM, Langdon SP, Miller WR (1995) c-erbB growth-factor-receptor proteins in ovarian tumours. Int J Cancer 64(3): 202-206
50. Sinn BV, Darb-Esfahani S, Wirtz RM, Faggad A, Weichert W, Buckendahl AC, Noske A, Müller BM, Budczies J, Sehouli J, Braicu EI, Dietel M, Denkert C (2009) Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fixed paraffin-embedded tissue. Virchows Arch 455(6): 461-467
51. Sḱrnisdóttir I, Sorbe B (2007) Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III-IV) epithelial ovarian carcinoma. Int J Oncol 30(3): 727-734
52. Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Moriya T, Sugiyama T (2006) Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94(10): 1369-1374
53. Tan DS, Iravani M, McCluggage WG, Lambros MB, Milanezi F, Mackay A, Gourley C, Geyer FC, Vatcheva R, Millar J, Thomas K, Natrajan R, Savage K, Fenwick K, Williams A, Jameson C, El-Bahrawy M, Gore ME, Gabra H, Kaye SB, Ashworth A, Reis-Filho JS (2011) Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res 17(6): 1521-1534
54. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, ChiewYE,Haviv I, GertigD,DeFazio A, BowtellDD, GroupAOCS (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14(16): 5198-5208
55. Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11(10): 719-725
56. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS, Group EOfRaToC-GC Group NCT (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10): 943-953
57. Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A, Group AGOOCS (2007) Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 106(1): 69-74
58. Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, Harter P, Pfisterer J, du Bois A (2010) Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol 17(6): 1642-1648
59. Winter WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP, Group GO (2008) Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 26(1): 83-89